Cart
×
Capricor Therapeutics – Webinar on Upcoming Clinical Trial for Cardiac Indication in Duchenne
There has been a lot of recent Duchenne research news lately. As a community, we are glad to see a variety of research programs moving forward with positive results. This provides hope for all those that live with Duchenne and their families.
Duchenne is a complex disease and will require a variety of treatments to address all aspects of the disease from replacing the missing protein; upregulating other proteins: addressing inflammation and fibrosis; and preventing cardiac failure, the primary cause of death for those with Duchenne.
We are hosting a webinar tomorrow with Capricor Therapeutics, Inc. to discuss Capricor’s upcoming HOPE-DUCHENNE clinical trial. The HOPE-DUCHENNE trial will evaluate CAP-1002 for the first time in patients with Duchenne with significant cardiac dysfunction. CAP-1002 is Capricor’s allogeneic, cardiosphere-derived cell (CDC) therapy already in clinical development for the treatment of heart disease.
Speakers include:
- Dr. Linda Marbán, Chief Executive Officer of Capricor Therapeutics
- Dr. Andrew Hamer, Vice President of Medical Affairs of Capricor
- Debra Miller, Founder and Chief Executive Officer of CureDuchenne
- Dr. Michael Kelly, Chief Scientific Advisor for CureDuchenne
We invite participants to join the webinar on Friday, June 19, 2015 at 3:00 p.m. ET/noon PT. To join the webinar please call (844) 337-8088 and enter conference ID number 64152106. Visit here to register online.
Here are links to other recent research updates:
Akashi Reports Positive Clinical Data on HT-100
Santhera Update on Pre-NDA Meeting with FDA on Raxone®/Catena® in Duchenne Muscular Dystrophy (DMD)
